Tumor Models

Tumor Models

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

• A large collection of cell line-derived xenograft (CDX) tumor models with an imaging based orthotopic/metastatic CDX platform covering 16 tumor types
• Patient-derived xenograft (PDX) tumor models covering 20 cancer types, drug resistant model and mouse clinical trial enabling translational research
• Syngeneic tumor models covering 20 cancer types, enabled with immunotherapy SOC, TIL analysis and RNAseq profiling.
• Human immune checkpoint gene KI mouse models
• hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

• 280+ validated models covering full range of cancer types
• 77+ cell lines derived from PDX models
• Available data of sensitivities to SOC (standard of care)
• Imaging-based orthotopic/metastatic tumor models
• Brain/bone metastatic models of lung/breast cancer cell lines

*: validated with SOC compound

28 Luciferase Labelled Orthotopic/Metastatic Tumor Models

• Cover 16 tumor types
• Bioluminescent imaging system in SPF barrier

Patient-derived xenograft (PDX) tumor models

• 1380+ PDX models covering full range of cancer types
• Fully-characterized models with genetic, molecular and pharmacological profiling
• Drug-resistant PDX models available
• in vitro screening and derivative PDXC/PDXO models
• IO-PDX panel with hPBMC humanization

A Comprehensive PDX Collection of Asia Prevalent Tumors

Syngeneic tumor models

• 70 Syngeneic models (mouse, rat, hamster)
• Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
• Tumor-infiltrating leukocytes (TILs) map
• WES, RNA-seq and scRNA-seq characterization

Genetically engineered models

• 48 engineered cell lines based on construct overexpression or gene knock-in
• Pharmacologically validated in vitro and in vivo
• Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization
• Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1, etc.

hPBMC/HSC Humanized Models

hPBMC Humanized Models

• Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
• Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation etc.)
• Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

• Available humanized models from CIEA, combine with WuXi PDX/CDX models.
• Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

A List of Established hPBMC Humanized Models

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.

• Collection of various targets and background mouse strains
• Validated with launched or most advanced clinical grade checkpoint antibodies
• Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3 etc.)

Immuno-avatar humanized models

• Mouse models harboring human tumor and human immune ceils
• Three different diagram of hPBMC humanization for mature T cell engraftment
• HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC etc.)
• IO-CDX and IO-PDX models with cancer targets and HLA information

Drug-resistant models

• Engineered cell line derived xenograft models
• Acquired drug-resistant CDX and PDX models
• Intrinsic drug-resistant PDX models